Cost-effectiveness of self-injected DMPA-SC compared with health-worker-injected DMPA-IM in Senegal.

Cost-effectiveness DMPA-SC Economic evaluation Family planning Injectable contraception Self-injection

Journal

Contraception: X
ISSN: 2590-1516
Titre abrégé: Contracept X
Pays: United States
ID NLM: 101767748

Informations de publication

Date de publication:
2019
Historique:
received: 25 04 2019
revised: 26 09 2019
accepted: 29 09 2019
entrez: 5 6 2020
pubmed: 1 1 2019
medline: 1 1 2019
Statut: ppublish

Résumé

To evaluate the cost-effectiveness of self-injected subcutaneous depot medroxyprogesterone acetate (DMPA-SC) compared to health-worker-administered intramuscular DMPA (DMPA-IM) in Senegal and to assess how including practice or demonstration injections in client self-injection training affects estimates. We developed a decision-tree model with a 12-month time horizon for a hypothetical cohort of 100,000 injectable contraceptive users in Senegal. We used the model to estimate incremental costs per disability-adjusted life year (DALY) averted. The analysis derived model inputs from DMPA-SC self-injection continuation and costing research studies and peer-reviewed literature. We evaluated the cost-effectiveness from societal and health system perspectives and conducted one-way and probabilistic sensitivity analyses to test the robustness of results. Compared to health-worker-administered DMPA-IM, self-injected DMPA-SC could prevent 1402 additional unintended pregnancies and avert 204 maternal DALYs per year for this hypothetical cohort. From a societal perspective, self-injection costs less than health worker administration regardless of the training approach and is therefore dominant. From the health system perspective, self-injection is dominant compared to health worker administration if a one-page instruction sheet is used and one additional DMPA-SC unit is used for training and is cost-effective at $208 per DALY averted when two additional DMPA-SC units are used. Sensitivity analysis showed estimates were robust. Self-injected DMPA-SC averted more pregnancies and DALYs and cost less from the societal perspective compared to health-worker-administered DMPA-IM and hence is dominant. Using fewer DMPA-SC units for practice or demonstration improves cost-effectiveness of self-injection from the health system perspective. Evidence from Senegal shows that self-injection of DMPA-SC can be dominant or cost-effective from both health system and societal perspectives relative to DMPA-IM from health workers even if women practice injecting or health workers demonstrate with one or two DMPA-SC units. Evidence on whether practice or demonstration is required for client training would be useful.

Identifiants

pubmed: 32494776
doi: 10.1016/j.conx.2019.100012
pii: S2590-1516(19)30011-5
pii: 100012
pmc: PMC7252428
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100012

Informations de copyright

© 2019 The Authors.

Références

Contraception. 2019 Feb;99(2):137-141
pubmed: 30439358
Contraception. 2017 Mar;95(3):306-311
pubmed: 27789309
Lancet Glob Health. 2018 May;6(5):e568-e578
pubmed: 29526707
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
Hum Reprod. 2008 Jun;23(6):1338-45
pubmed: 18372257
PLoS One. 2015 Nov 11;10(11):e0142550
pubmed: 26560140
Int Perspect Sex Reprod Health. 2015 Mar;41(1):11-9
pubmed: 25856233
PLoS One. 2011 Mar 28;6(3):e18193
pubmed: 21464895
Contraception. 2012 May;85(5):458-64
pubmed: 22079602
Contraception. 2017 Sep;96(3):203-210
pubmed: 28673645
Contraception. 2018 Nov;98(5):389-395
pubmed: 29859148
Contraception. 2018 Mar;97(3):198-204
pubmed: 29246818
Contraception. 2012 May;85(5):453-7
pubmed: 22079605
Contraception. 2018 Nov;98(5):411-417
pubmed: 30120925
Contraception. 2018 Nov;98(5):383-388
pubmed: 29654751
Contraception. 2014 May;89(5):379-84
pubmed: 24529492
Pharmacoeconomics. 2000 May;17(5):479-500
pubmed: 10977389
Contraception. 2018 Nov;98(5):405-410
pubmed: 29706227
Contraception. 2018 Nov;98(5):396-404
pubmed: 30098940
Contraception. 2014 May;89(5):352-6
pubmed: 24656555
Lancet Glob Health. 2018 May;6(5):e481-e482
pubmed: 29526706

Auteurs

Mercy Mvundura (M)

PATH, PO Box 900922, Seattle, WA 98109, USA.

Laura Di Giorgio (L)

PATH, PO Box 900922, Seattle, WA 98109, USA.

Chloe Morozoff (C)

PATH, PO Box 900922, Seattle, WA 98109, USA.

Jane Cover (J)

PATH, PO Box 900922, Seattle, WA 98109, USA.

Marguerite Ndour (M)

PATH, BP 15115, Dakar-Fann, Dakar, Senegal.

Jennifer Kidwell Drake (JK)

PATH, PO Box 900922, Seattle, WA 98109, USA.

Classifications MeSH